$1.34 0.13 (+10.74%)
11/6/2009 3:59 PM

CombinatoRx, Inc. (CRXX)

CAPS Rating: 5 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Current Price $1.34 Mkt Cap $46.99M
Open $1.24 P/E Ratio 0.00
Prev. Close $1.21 Div. (Yield) N/A (N/A)
Daily Range $1.19 - $1.35 Volume 239,190
52-Wk Range $0.25 - $2.60 Avg. Daily Vol. 526,000

CRXX News and Commentary

Related News and Articles

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

43 Outperform
4 Underperform
 

All-Star Members

11 Outperform
0 Underperform
 

Wall Street

5 Outperform
0 Underperform
 

Top CRXX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Cosmo21 (< 20)
Submitted April 01, 2008

CRXX has a great pipeline and plenty of cash. Just a matter of time untill one of it's many phase II drugs is approved and a partner moves in. Buy now before it.s to late!

1 Comment | Reply | Report this Post

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CRXX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about CRXX.

Recs

0
Member Avatar thecyberguy (58.61) Submitted: 6/5/2008 2:37:32 PM : Underperform Start Price: $3.85 CRXX Score: +44.71

Who??

Report this Post 0 Comments | Reply | Permalink

Recs

1
Member Avatar Cosmo21 (< 20) Submitted: 4/1/2008 6:11:02 PM : Outperform Start Price: $3.21 CRXX Score: -39.19

CRXX has a great pipeline and plenty of cash. Just a matter of time untill one of it's many phase II drugs is approved and a partner moves in. Buy now before it.s to late!

Report this Post 1 Comment | Reply | Permalink

Recs

0
Member Avatar zzlangerhans (99.36) Submitted: 3/17/2008 11:46:40 AM : Outperform Start Price: $3.90 CRXX Score: -53.04

Another small-cap biotech knocked down to an all-time low in the absence of clear negative catalysts. Their pipeline appears to be proceeding well with encouraging phase II data for CRx-191 in psoriasis, and several other phase II trials in progress. The generic combo concept seems a little bargain basement, but the upside potential of new treatments for common diseases such as arthritis and diabetes cannot be ignored - witness the mad overreaction Rigel got with phase II data. Financials also appear strong with cash position more than 100M and a manageable burn. Eeventually this worm will turn and beaten down baby biotechs will recover.

Report this Post 0 Comments | Reply | Permalink
View All 10 Pitches »

Leaderboard

Find the members with the highest scoring picks in CRXX.

Score Leader

ValueRider

ValueRider (99.19) Score: +99.54

The Score Leader is the member with the highest score across all their picks in CRXX.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
raisethesky < 20 9/18/2007 Underperform NS $6.00 -77.67% -24.41% +53.26
thecyberguy 58.61 6/5/2008 Underperform 1Y $3.85 -65.19% -20.48% +44.71 1 Comment
spolack < 20 4/1/2008 Underperform NS $3.24 -58.64% -18.04% +40.60
dozer963 < 20 4/8/2008 Underperform NS $3.26 -58.90% -18.45% +40.44
Cosmo21 < 20 4/2/2008 Outperform 1Y $3.21 -58.26% -19.06% -39.19 2 Comments
JMC23 93.95 5/15/2008 Outperform 1Y $3.74 -64.17% -21.31% -42.86
PrestonPysh < 20 6/3/2008 Outperform NS $3.65 -63.29% -20.25% -43.04
GreedsGood04 50.11 6/3/2008 Outperform 1Y $3.65 -63.29% -20.25% -43.04
Biotech2008 89.46 1/7/2008 Outperform NS $4.33 -69.05% -21.27% -47.78 1 Comment
MoeLarryShemp 62.84 1/3/2008 Outperform 5Y $4.66 -71.24% -23.18% -48.07
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackLadenburg 46.65 7/28/2008 Outperform NS $3.90 -79.48% -15.33% -64.16 10/6/2008 @ $0.80
TrackPZK < 20 2/19/2008 Outperform NS $5.30 -74.72% -18.14% -56.57
TrackPiperJaff 80.38 1/3/2008 Outperform NS $5.00 -73.20% -22.95% -50.25
TrackEveillard 89.92 9/30/2007 Outperform NS $6.25 -78.56% -26.44% -52.12 2 Comments
TrackLazardCapit < 20 1/23/2007 Outperform NS $8.24 -83.74% -20.07% -63.67
TrackRodmanRen < 20 1/5/2007 Outperform NS $8.15 -83.56% -19.54% -64.01

Featured Broker Partners